Multiple System Atrophy (MSA) Therapeutics Market is likely to propel to US$ 211.1 Million by 2033

The global Multiple System Atrophy (MSA) Therapeutics Market is currently worth US$ 137.3 million in 2023 and is expected to grow at a CAGR of 4.4%. Because of technological advancements in healthcare, the market is expected to reach US$ 211.1 million by 2033. The market for multiple system atrophy is expected to grow significantly, owing to an increase in neurodegenerative disorders.

The multiple system atrophy market is expected to grow in the coming years as a result of a new type of drug launch. Because of the loss of patent protection, new players are expected to enter the multiple system atrophy market during the forecast years.

Furthermore, increasing government support and awareness about neurodegenerative disorders drive market growth. Increased healthcare spending in developing countries and growth in

The manufacturers are involved in the production of multiple system atrophy therapeutics in a larger capacity. Research and innovation are also conducted to launch innovative products for multiple system atrophy therapeutics. For instance, Teva Pharmaceutical Industries Ltd. and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. Anle138b targets pathological alpha-synuclein oligomers and is being evaluated in patients with neurodegenerative diseases for potential disease modification.

Download Sample Copy @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16285

North America dominates the multiple system atrophy therapeutics market due to the presence of key market players’ presence, along with recent product launches and established healthcare infrastructure, which will accelerate the market’s growth in the region. The significant R&D investments in Europe abode well for market growth.

Key Takeaways from the Market Study

As of 2023, the multiple system atrophy therapeutics market was valued at US$137.3 Million
From 2023 to 2033, the multiple system atrophy therapeutics industry is poised to grow at an 4.4% CAGR
By 2033, the multiple system atrophy therapeutics market is slated to reach a valuation of US$211.1 Million
Based on diagnosis, PET scan segment dominated the market in 2023 with a revenue share of 34.6%.
China is poised to yield a CAGR of 4.1% with respect to multiple system atrophy therapeutics through 2033

“Growing healthcare spending and increase in the prevalence of neurological disorders are expected to radically transform the multiple system atrophy therapeutics market in the coming years,” comments an analyst at FMI.

Have a Conversation with the Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16285

Competitive Landscape

are some of the key players in the chronic smell and flavour loss treatment market like Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, Theravance Biopharma, Inc., Merck & Co., Neuropore Therapies Inc, Newron Pharmaceuticals SpA, ProMIS Neurosciences Inc, Stealth BioTherapeutics Corp, Chelsea Therapeutics International, Ltd. and others.

The manufacturers are involved in the production of multiple system atrophy(MSA) therapeutics larger capacity. Research and innovation are also conducted to launch innovative products for multiple system atrophy(MSA) therapeutics.

In April 2022, ProMIS Neurosciences, Inc. a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteinssuch as toxic oligomers implicated in the development of neurodegenerative diseases, announced today new milestones in potential therapeutic approaches for ALS.
In October 2022, Biohaven Ltd. announced advancements in the development of its MoDE extracellular target degrader platform technology licensed from Yale University for various disease indications, including, but not limited to, neurological disorders, cancer, infectious and autoimmune diseases.

Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-16285

Key Segments Covered in the Multiple System Atrophy (MSA) Market Industry Survey

Multiple System Atrophy (MSA) Therapeutics Market by Type:

Parkinsonian
Cerebellar

Multiple System Atrophy (MSA) Therapeutics Market by Diagnosis:

Magnetic Resonance Imaging (MRI)
Positron Emission Tomography (PET)
Single Photon Emission Computed Tomography (SPECT)
Tilt Table Test
Others

Multiple System Atrophy (MSA) Therapeutics Market by RegionP:

North America
Latin America
Europe
South Asia
East Asia
Oceania
MEA

About Us

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiriessales@futuremarketinsights.com
Websitehttps://www.futuremarketinsights.com
LinkedInTwitterBlogs

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these